Page 2 - Commercial Platform News Today

Athenex, Inc. (NASDAQ:ATNX – Get Rating) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 414,600 shares, a drop of 13.3% from the March 15th total of 478,000 shares. Approximately 5.7% of the company’s shares are sold short. Based on […]

Athenex, Inc. (NASDAQ:ATNX – Get Rating) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 478,000 shares, an increase of 20.6% from the February 28th total of 396,400 shares. Based on an average daily volume of 243,000 shares, the short-interest ratio is currently […]

Press release content from PR Newswire. The AP news staff was not involved in its creation.

New Jersey, USA---- 06/02/2022-- The latest study released on the Global Peer to Peer Insurance Market by AMA Research evaluates market size, trend, and forecast to 2027. The Peer to Peer Insurance market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have...

New Jersey, USA---- 05/28/2022-- The latest study released on the Global Peer to Peer Insurance Market by AMA Research evaluates market size, trend, and forecast to 2027. The Peer to Peer Insurance market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have...

New Jersey, USA---- 05/26/2022-- The latest study released on the Global Peer to Peer Insurance Market by AMA Research evaluates market size, trend, and forecast to 2027. The Peer to Peer Insurance market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have...

Zacks Investment Research cut shares of Athenex (NASDAQ:ATNX – Get Rating) from a buy rating to a hold rating in a research note published on Friday, Zacks.com reports. According to Zacks, “Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company’s […]

Zacks Investment Research upgraded shares of Athenex (NASDAQ:ATNX – Get Rating) from a hold rating to a buy rating in a research report released on Monday, Zacks.com reports. Zacks Investment Research currently has $1.00 price target on the stock. According to Zacks, “Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery […]

BUFFALO, N.Y., March 14, 2022 -- Athenex , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and... | March 14, 2022

BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...